Clinical Trial Update: CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating CIK cell transfusion plus adjuvant chemotherapy for stage IB-IIIA non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Cytokine-induced killer (CIK) cells (cytokine-induced killer cells)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN